RT Journal Article
SR Electronic
T1 Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.12.21251294
DO 10.1101/2021.02.12.21251294
A1 E Wangeci Kagucia
A1 John N Gitonga
A1 Catherine Kalu
A1 Eric Ochomo
A1 Benard Ochieng
A1 Nickline Kuya
A1 Angela Karani
A1 James Nyagwange
A1 Boniface Karia
A1 Daisy Mugo
A1 Henry K Karanja
A1 James Tuju
A1 Agnes Mutiso
A1 Hosea Maroko
A1 Lucy Okubi
A1 Eric Maitha
A1 Hossan Ajuck
A1 Mary Bogita
A1 Richmond Mudindi
A1 David Mukabi
A1 Wycliffe Moracha
A1 David Bulimu
A1 Nelson Andanje
A1 Evans Shiraku
A1 Rosemary Okuku
A1 Monicah Ogutu
A1 Rashid Aman
A1 Mercy Mwangangi
A1 Patrick Amoth
A1 Kadondi Kasera
A1 Wangari Ng’ang’a
A1 Rodgers Mariga
A1 Tobias Munabi
A1 Susan M Ramadhan
A1 Janet Mwikali
A1 Rose Nasike
A1 Cornelius Andera
A1 Roselyne Nechesa
A1 Benson K Kiplagat
A1 Julius Omengo
A1 Simon Oteba
A1 Arthur Mwangi
A1 Dorcas Mkanyi
A1 George Karisa
A1 Judith K Migosi
A1 Patrick Msili
A1 Samson Mwambire
A1 Anthony M Boniface
A1 Amek Nyaguara
A1 Shirine Voller
A1 Mark Otiende
A1 Christian Bottomley
A1 Charles N Agoti
A1 Lynette I Ochola-Oyier
A1 Ifedayo M O Adetifa
A1 Anthony O Etyang
A1 Katherine E Gallagher
A1 Sophie Uyoga
A1 Edwine Barasa
A1 Philip Bejon
A1 Benjamin Tsofa
A1 Ambrose Agweyu
A1 George M Warimwe
A1 J Anthony G Scott
YR 2021
UL http://medrxiv.org/content/early/2021/02/17/2021.02.12.21251294.abstract
AB In October 2020, anti-SARS-CoV-2 IgG seroprevalence among truck drivers and their assistants (TDA) in Kenya was 42.3%, higher than among other key populations. TDA transport essential supplies during the COVID-19 pandemic, placing them at increased risk of being infected and of transmitting SARS-CoV-2 infection over a wide geographical area.Competing Interest StatementRA, MM, KK and PA are from the Ministry of Health, Government of Kenya. All other authors declare no competing interests.Funding StatementThis project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated programme of SARS-CoV-2 serosurveillance in Kenya led by KEMRI-Wellcome Trust Research Programme. The views expressed in this publication are those of the authors and not necessarily those of the funding agencies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kenya Medical Research Institute Scientific and Ethics Review CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data may be requested through the KEMRI-Wellcome Trust Research Programme Data Governance CommitteeCOVID-19Coronavirus disease 2019CPHSCounty public health staffELISAEnzyme-linked immunosorbent assayHCWHealthcare workersNATNucleic acid test/ testingNP/OPNasopharyngeal/ oropharyngealODOptical densityOSBPOne Stop Border PostSARS-CoV-2Severe acute respiratory syndrome coronavirus 2TDATruck drivers and assistants